International Journal of Colorectal Disease

, Volume 22, Issue 12, pp 1445–1451 | Cite as

Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial

  • Ahmed Madisch
  • Stephan Miehlke
  • Otto Eichele
  • Jenny Mrwa
  • Birgit Bethke
  • Eberhard Kuhlisch
  • Elke Bästlein
  • Georg Wilhelms
  • Andrea Morgner
  • Bernd Wigginghaus
  • Manfred Stolte
Original Article

Abstract

Background and aims

The objective of this study was to investigate the effect of Boswellia serrata extract (BSE) on symptoms, quality of life, and histology in patients with collagenous colitis.

Materials and methods

Patients with chronic diarrhea and histologically proven collagenous colitis were randomized to receive either oral BSE 400 mg three times daily for 6 weeks or placebo. Complete colonoscopy and histology were performed before and after treatment. Clinical symptoms and quality of life were assessed by standardized questionnaires and SF-36. The primary endpoint was the percentage of patients with clinical remission after 6 weeks (stool frequency ≤3 soft /solid stools per day on average during the last week). Patients of the placebo group with persistent diarrhea received open-label BSE therapy for a further 6 weeks.

Results

Thirty-one patients were randomized; 26 patients were available for per-protocol-analysis. After 6 weeks, the proportion of patients in clinical remission was higher in the BSE group than in the placebo group (per protocol 63.6%; 95%CI, 30.8–89.1 vs 26.7%, 95%CI, 7.7–55.1; p = 0.04; intention-to-treat 43.8% vs 26.7%, p = 0.25). Compared to placebo, BSE treatment had no effect on histology and quality of life. Five patients discontinued BSE treatment prematurely. Discontinuation was due to adverse events (n = 1), unwillingness to continue (n = 3), or loss to follow-up for unknown reasons (n = 1). Seven patients received open-label BSE therapy, five of whom achieved complete remission.

Conclusions

Our study suggests that BSE might be clinically effective in patients with collagenous colitis. Larger trials are clearly necessary to establish the clinical efficacy of BSE.

Keywords

Microscopic colitis Collagenous colitis Boswellia serrata extract 

References

  1. 1.
    Fernandez-Banares F, Salas A, Forne M, Esteve M, Espinos J, Viver JM (1999) Incidence of collagenous and lymphocytic colitis: a 5-year population-based study. Am J Gastroenterol 94:418–423CrossRefPubMedGoogle Scholar
  2. 2.
    Bohr J, Tysk C, Eriksson S, Jarnerot G (1995) Collagenous colitis in Orebro, Sweden, an epidemiological study 1984–1993. Gut 37:394–397CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Agnarsdottir M, Gunnlaugsson O, Orvar KB, Cariglia N, Birgisson S, Bjornsson S, Thorgeirsson T, Jonasson JG (2002) Collagenous and lymphocytic colitis in Iceland. Dig Dis Sci 47:1122–1128CrossRefPubMedGoogle Scholar
  4. 4.
    Tremaine WJ (2000) Collagenous colitis and lymphocytic colitis. J Clin Gastroenterol 30:245–249CrossRefPubMedGoogle Scholar
  5. 5.
    Pardi DS (2004) Microscopic colitis. An update. Inflamm Bowel Dis 10:860–870CrossRefPubMedGoogle Scholar
  6. 6.
    Bohr J, Olesen M, Tysk C, Järnerot G (2000) Collagenous and lymphocytic colitis: a clinical and histopathological review. Can J Gastroenterol 14:943–947CrossRefPubMedGoogle Scholar
  7. 7.
    Veress B, Lofberg R, Bergman L (1995) Microscopic colitis syndrome. Gut 36:880–886CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Lazenby AJ, Yardley JH, Giardiello FM, Jessurun J, Bayless TM (1989) Lymphocytic (microscopic) colitis: a comparative histopathologic study with particular reference to collagenous colitis. Hum Pathol 20:18–28CrossRefPubMedGoogle Scholar
  9. 9.
    Stolte M, Ritter M, Borchard F, Koch-Scherrer G (1990) Collagenous gastroduodenitis on collagenous colitis. Endoscopy 22:186–187CrossRefPubMedGoogle Scholar
  10. 10.
    Carpenter HA, Tremaine WJ, Batts KP, Czaja AJ (1992) Sequential histologic evaluations in collagenous colitis. Correlations with disease behavior and sampling strategy. Dig Dis Sci 37:1903–1909CrossRefPubMedGoogle Scholar
  11. 11.
    Armes J, Gee DC, Macrae FA, Schroeder W, Bhathal PS (1992) Collagenous colitis: jejunal and colorectal pathology. J Clin Pathol 45:784–787CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Bohr J, Tysk C, Yang P, Danielsson D, Jarnerot G (1996) Autoantibodies and immunoglobulins in collagenous colitis. Gut 39:73–76CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Jarnerot G, Tysk C, Bohr J et al (1995) Collagenous colitis and fecal stream diversion. Gastroenterology 109:449–455CrossRefPubMedGoogle Scholar
  14. 14.
    Duerr RH, Targan SR, Landers CJ et al (1991) Anti-neutrophil cytoplasmic antibodies in ulcerative colitis: comparison with other colitides/diarrheal illnesses. Gastroenterology 100:1590–1596CrossRefPubMedGoogle Scholar
  15. 15.
    Beaugerie L, Pardi DS (2005) Review article: drug-induced microscopic colitis-proposal for a scoring system and review of the literature. Aliment Pharmacol Ther 22:277–284CrossRefPubMedGoogle Scholar
  16. 16.
    Fine K, Ogunji F, Lee E, Lafon G, Tanzi M (1999) Randomized, double-blind placebo-controlled trial of bismuth subsalicylate for microscopic colitis (abstr.). Gastroenterology 166:A880Google Scholar
  17. 17.
    Baert F, Schmit A, D’Haens G, Dedeurwaerdere F, Louis E, Cabooter M, De Vos M, Fontaine F, Naegels S, Schurmans P, Stals H, Geboes K, Rutgeerts P (2002) Budesonide in collagenous colitis-a double-blind placebo-controlled trial with histological follow-up. Gastroenterology 122:20–25CrossRefPubMedGoogle Scholar
  18. 18.
    Miehlke S, Heymer P, Bethke B, Bästlein E, Meier E, Bartram HP, Wilhelms G, Lehn N, Dorta G, DeLarive J, Tromm A, Bayerdörffer E, Stolte M (2002) Budesonide treatment for collagenous colitis–a randomized, double-blind, placebo-controlled, multicenter trial. Gastroenterology 123:978–984CrossRefPubMedGoogle Scholar
  19. 19.
    Bonderup OK, Hansen JB, Birket-Smith L, Vestergaard V, Teglbjaerg PS, Fallingborg J (2003) Budesonide treatment of collagenous colitis: a randomised, double blind, placebo controlled trial with morphometric analysis. Gut 52:248–251CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Madisch A, Heymer P, Voss C, Wigginghaus B, Bastlein E, Bayerdorffer E, Meier E, Schimming W, Bethke B, Stolte M, Miehlke S (2005) Oral budesonide therapy improves quality of life in patients with collagenous colitis. Int J Colorectal Dis 20:312–316CrossRefPubMedGoogle Scholar
  21. 21.
    Miehlke S, Madisch A, Bethke B, Stolte M (2005) Time to remission with budesonide in collagenous colitis. Aliment Pharmacol Ther 21:1507–1508CrossRefPubMedGoogle Scholar
  22. 22.
    Miehlke S, Madisch A, Voss C, Morgner A, Heymer P, Kuhlisch E, Bethke B, Stolte M (2005) Long-term follow-up of collagenous colitis after induction of clinical remission with budesonide. Aliment Pharmacol Ther 22:1115–1119CrossRefPubMedGoogle Scholar
  23. 23.
    Gupta I, Gupta V, Parihar A, Gupta S, Ludtke R, Safayhi H, Ammon HP (1998) Effects of Boswellia serrata gum resin in patients with bronchial asthma: results of a double-blind, placebo-controlled, 6-week clinical study. Eur J Med Res 3:511–514PubMedGoogle Scholar
  24. 24.
    Sander O, Herborn G, Rau R (1998) Is H15 (resin extract of Boswellia serrata, “incense”) a useful supplement to established drug therapy of chronic polyarthritis? Results of a double-blind pilot study. Z Rheumatol 57(1):11–16CrossRefPubMedGoogle Scholar
  25. 25.
    Kimmatkar N, Thawani V, Hingorani L, Khiyani R (2003) Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee–a randomized double blind placebo controlled trial. Phytomedicine 10:3–7CrossRefPubMedGoogle Scholar
  26. 26.
    Gerhardt H, Seifert F, Buvari P, Vogelsang H, Repges R (2001) Therapy of active Crohn disease with Boswellia serrata extract H 15. Z Gastroenterol 39:11–17CrossRefPubMedGoogle Scholar
  27. 27.
    Gupta I, Parihar A, Malhotra P, Singh GB, Ludtke R, Safayhi H, Ammon HP (1997) Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res 2:37–43PubMedGoogle Scholar
  28. 28.
    Gupta I, Parihar A, Malhotra P, Gupta S, Ludtke R, Safayhi H, Ammon HP (2001) Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med 67:391–395CrossRefPubMedGoogle Scholar
  29. 29.
    Chande N, McDonald JW, Macdonald JK (2005) Interventions for treating collagenous colitis. Cochrane Database Syst Rev 19:CD003575Google Scholar
  30. 30.
    Madisch A, Miehlke S, Eichele E, Bethke B, Mrwa J, Wilhelms G, Debus M, Bästlein E, Kuhlisch E, Stolte M (2005) Boswellia Serrata Extract for the Treatment of collagenous colitis: a randomized, double-Blind, placebo-controlled, multicenter Trial. Gastroenterology 128:A581Google Scholar
  31. 31.
    Sailer ER, Schweizer S, Boden SE, Ammon HP, Safayhi H (1998) Characterization of an acetyl-11-keto-beta-boswellic acid and arachidonate-binding regulatory site of 5-lipoxygenase using photoaffinity labeling. Eur J Biochem 256:364–368CrossRefPubMedGoogle Scholar
  32. 32.
    Safayhi H, Mack T, Sabieray J Anazodo MI, Subramanian LR, Ammon HP (1992) Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J Pharmacol Exp Ther 261/3:1143–1146Google Scholar
  33. 33.
    Safayhi H, Sailer ER, Ammon HPT (1995) Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-ß-boswellic acid. Mol Pharmacol 47:1212–1216PubMedGoogle Scholar
  34. 34.
    Safayhi H, Sailer ER, Ammon HPT (1996) 5-lipoxygenase inhibition by acetyl-11-keto-ß-boswellic acid (AKBA) by a novel mechanism. Phytomedicine 3/1:71CrossRefGoogle Scholar
  35. 35.
    Krieglstein CF, Anthoni C, Rijcken EJ, Laukotter M, Spiegel HU, Boden SE, Schweizer S, Safayhi H, Senninger N, Schurmann G (2001) Acetyl-11-keto-beta-boswellic acid, a constituent of a herbal medicine from Boswellia serrata resin, attenuates experimental ileitis. Int J Colorectal Dis 16:88–95CrossRefPubMedGoogle Scholar
  36. 36.
    Syrovets T, Buchele B, Gedig E, Slupsky JR, Simmet T (2000) Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and II alpha. Mol Pharmacol 58:71–81PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Ahmed Madisch
    • 1
  • Stephan Miehlke
    • 1
  • Otto Eichele
    • 2
  • Jenny Mrwa
    • 1
  • Birgit Bethke
    • 3
  • Eberhard Kuhlisch
    • 4
  • Elke Bästlein
    • 5
  • Georg Wilhelms
    • 6
  • Andrea Morgner
    • 1
  • Bernd Wigginghaus
    • 7
  • Manfred Stolte
    • 3
  1. 1.Medical Department ITechnical University HospitalDresdenGermany
  2. 2.PharmacistKoblenzGermany
  3. 3.Institute for PathologyKlinikum BayreuthBayreuthGermany
  4. 4.Institute of Medical Informatics and BiometryTechnical University HospitalDresdenGermany
  5. 5.CologneGermany
  6. 6.GoslarGermany
  7. 7.OsnabrückGermany

Personalised recommendations